Enzo Biochem, a renowned life sciences company with over four decades of industry experience, has made a strategic decision to delist its common stock from the New York Stock Exchange (NYSE) and transition trading activities to the OTCQX Best Market (OTCQX). This move, communicated to the NYSE on March 28, 2025, involves a forthcoming filing with the Securities and Exchange Commission (SEC) to formalize the delisting process, expected to culminate around April 17, 2025, followed by trading initiation on OTCQX by April 18, 2025.

The motivation behind this significant shift stems from Enzo Biochem’s response to non-compliance notices issued by the NYSE regarding certain listing standards related to market capitalization, stockholder’s equity, and average closing stock price. In evaluating available remedies to address these deficiencies, the company’s Board of Directors has opted for a voluntary delisting from NYSE and the subsequent transfer of stock trading to OTCQX as a more favorable course of action.

Enzo Biochem has proactively sought approval to quote its common stock on OTCQX, ensuring a seamless transition for shareholders without necessitating any share exchanges. This decision underscores the company’s commitment to maintaining transparency and compliance with SEC reporting regulations post-delisting from NYSE. Additionally, electronic trading continuity is anticipated without material disruptions, preserving shareholder interests and market stability.

Established over 45 years ago, Enzo Biochem operates primarily through its Life Sciences division, Enzo Life Sciences, specializing in cutting-edge labeling and detection technologies across various research domains, from genomics to cell analysis. The company’s diverse product portfolio encompasses high-quality offerings such as antibodies, genomic probes, assays, and proteins, playing pivotal roles in translational research and pharmaceutical development endeavors.

Enzo Biochem’s forward-looking approach emphasizes its dedication to sustaining technological innovation and market competitiveness. By navigating the transition to OTCQX with strategic foresight, the company aims to optimize trading efficiency and stakeholder value while upholding its commitment to regulatory compliance and operational excellence.